Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/25/22
Travere Therapeutics Reports Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 02/24/22
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 02/17/22
Travere Therapeutics to Report Fourth Quarter and Full Year 2021 Financial ResultsGlobeNewsWire • 02/10/22
Travere Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/09/22
Travere Posts Topline Data For Pegtibatinase In patients With Rare Metabolic DisorderBenzinga • 12/15/21
Travere Therapeutics Announces Positive Topline Results from the Ongoing Phase 1/2 COMPOSE Study of Pegtibatinase in Classical HomocystinuriaGlobeNewsWire • 12/15/21
Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021GlobeNewsWire • 11/02/21
Travere Therapeutics, Inc. (TVTX) CEO Eric Dube on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 10/29/21
Travere Therapeutics Reports Third Quarter 2021 Financial Results and Organizational ProgressGlobeNewsWire • 10/28/21
Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New ZealandBusiness Wire • 09/16/21
Travere Therapeutics and Vifor Pharma Announce Licensing Agreement for the Commercialization of Sparsentan in Europe, Australia and New ZealandGlobeNewsWire • 09/15/21
Travere Therapeutics Appoints Ruth Williams-Brinkley to its Board of DirectorsGlobeNewsWire • 09/14/21
Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study SuccessSeeking Alpha • 08/30/21
Travere Therapeutics Stock Is Trading Higher On Positive Data From Kidney Disease CandidateBenzinga • 08/16/21